Autoantibodies against malondialdehyde-modified lipoprotein(a) in antiphospholipid syndrome

Arthritis and Rheumatism

Volumn 42, Issue 12, 1999, Pages 2606-2611

  Romero, Fredeswinda I ^a   Atsumi, Tatsuya ^a   Tinahones, Francisco J ^b   Gómez Zumaquero, Juan M ^b   Amengual, Olga ^a   Khamashta, Munther A ^a   Hughes, Graham R V ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID ANTIBODY; PHOSPHOLIPID DERIVATIVE;

ADOLESCENT; ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CONTROLLED STUDY; CROSS REACTION; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOPROTEINS; HUMANS; LIPOPROTEIN(A); LIPOPROTEINS, LDL; MALE; MALONDIALDEHYDE; MIDDLE AGED;

EID: 0033510890     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199912)42:12<2606::AID-ANR14>3.0.CO;2-X     Document Type: Article

References (34)

1. Shoenfeld Y. The anti-phospholipid (Hughes) syndrome: a crossroads of autoimmunity and atherosclerosis. Lupus 1997;6:559-60.
2. Palinski W, Rosenfeld MF, Ylä-Herttuala S, Gurtner GC, Socher SS, Butler SW, et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci U S A 1989;86:1372-6.
3. Ylä-Herttuala S, Butler S, Picard S, Palinsky W, Steinberg D, Witztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes MDA-LDL and copper-oxidized LDL. Atherosclerosis 1991;11:1209-22.
4. Salonen JT, Yla-Hcrttuala S, Yamamoto L, Butler S, Korpela H, Salonen R, et al. Autoantihody against oxidized LDL and progression of carotid atherosclerosis. Lancet 1992;339:883-7.
5. Virella G, Virella Y, Leman RB, Pryor MB, Lopes-Virella MF. Anti oxidized low density lipoprotein antibodies in patients with coronary disease and normal healthy volunteers. Int J Clin Lab Res 1993;23:95-101.
6. Maggi E, Bellazzi R, Falaschi F, Frattoni A, Perani G, Finardi G, et al. Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis? Kidney Int 1994;45: 876-83.
7. Berg K. A new serum type system in man: the Lp(a) system. Acta Pathol Microbiol Scand 1963;59:369-82.
8. 1-lipoprotein in patients with coronary heart disease. Clin Genet 1974;6:230-5.
9. Dahlen G, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM Jr. Association of plasma levels of lipoprotein(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986;74:758-65.
10. Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Beisiegel U. Detection and quantification of lipoprotein (a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989;9:579-92.
11. Naruszewicz M, Selinger E, Davignon J. Oxidative modification of lipoprotein (a) and the effect of β-carotene. Metabolism 1992;11: 1215-24.
12. Haberland ME, Fless GM, Scanu AM, Fogelman AM. Malondialdehyde modification of lipoprotein (a) produces avid uptake by human monocyte-macrophages. J Biol Chem 1992;6:4143-51.
13. Ragab MS, Selvaraj P, Sgoutas DS. Oxidized lipoprotein (a) induces cell adhesion molecule Mac-1 (CD 11b) and enhances adhesion of the monocytic cell line U937 to cultured endothelial cells. Atherosclerosis 1996;123:103-13.
14. Hoff HF, O'Neil J, Yashiro A. Partial characterization of lipoproteins containing apo(a) in human atherosclerotic lesions. J Lipid Res 1993;34:789-98.
15. Lecert V, Alhenc-Gelas M, Laurian C, Bruneval P, Aiach M, Cormier JM, et al. Antiphospholipid antibodies and atherosclerosis. Am J Med 1992;92:575-6.
16. Amengual O, Atsumi T, Khamashta MA, Tinahones FJ, Hughes GRV. Autoantibodies against oxidized low-density lipoprotein in antiphospholipid syndrome. Br J Rheumatol 1997;36:964-8.
17. Atsumi T, Khamashta MA, Andújar C, Leandro MJ, Amengual O, Ames PRJ, et al. Elevated plasma lipoprotein (a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome. J Rheumatol 1998;25:69-73.
18. Harris EN. Antiphospholipid antibodies. Br J Haematol 1990;74: 1-9.
19. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
20. Palinsky W, Ylä-Herttuala S, Rosenfeld ME, Butler SW, Socher SA, Parthasarathy S, et al. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 1990;10:325-35.
21. Harris EN, Gharavi AE, Patel BM, Hughes GRV. Evaluation of the anticardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol 1987;68:215-22.
22. Amengual O, Atsumi T, Khamashta MA, Koike T, Hughes GRV. Specificity of ELISA for antibody to β2-glycoprotein I in patients with antiphospholipid syndrome. Br J Rheumatol 1996;35:1239-43.
23. Harpel PC, Gordon BR, Parker TS. Plasminogen catalyzes binding of lipoprotein(a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci U S A 1989;86:3847-51.
24. Utermann G. The mysteries of lipoprotein(a). Science 1989;246: 904-10.
25. Yamazaki M, Asakura H, Jokaji H, Saito M, Votani C, Kumabashiri I, et al. Plasma levels of lipoprotein(a) are elevated in patients with the antiphospholipid syndrome. Thromb Haemost 1994;71:424-7.
26. Marcovina SM, Zhang ZH, Gaur VP, Albers JJ. Identification of 34 apolipoprotein(a) isoforms: differential expression of apolipoprotein(a) alleles between American black and whites. Biochem Biophys Res Commun 1993;191:1192-6.
27. Bard JM, Delattre-Lestavel S, Clavey V, Pont P, Derudas B, Parra HJ, et al. Isolation and characterization of two subspecies of Lp(a), one containing apo E and one free of apo E. Biochim Biophys Acta 1992;1127:124-30.
28. Sattler W, Kostner GM, Waeg G, Esterbauer H. Oxidation of lipoprotein Lp(a): a comparison with low-density lipoprotein. Biochim Biophys Acta 1991;1081:65-74.
29. Kleinveld HA, Duif PF, van Rijn IIJ. Oxidation of lipoprotein(a) and low density lipoprotein containing density gradient ultracentrifugation fractions. Biochim Biophys Acta 1996;1303:15-21.
30. Wu R, Lefvert AK. Autoantibodies against oxidized low density lipoproteins (oxLDL): characterization of antibody isotype, subclass, affinity and effect on the macrophage uptake of oxLDL. Clin Exp Immunol 1995;102:174-80.
31. Mironova M, Virella G, Lopes-Virella MF. Isolation and characterization of human antioxidized LDL autoantibodies. Arterioscler Thromb Vasc Biol 1996;16:222-9.
32. Bellomo G, Maggi E, Poli M, Agosta FG, Bollati P, Finardi G. Autoantibodies against oxidatively modified low-density lipoproteins in NIDDM. Diabetes 1995;44:60-6.
33. Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T. Crossreaction between antibodies to oxidized low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993;341:923-5.
34. 2-glycoprotein I and oxidized low-density lipoprotein in patients with antiphospholipid syndrome. Br J Rheumatol 1998;37:746-9.